Rhythm Biosciences Ltd (ASX:RHY) managing director & CEO Trevor Lockett speaks to Proactive Investors about the health company’s development of a diagnostic tool for detecting colorectal or bowel cancer.
ColoSTAT, Rhythm’s antibody-based blood test, was granted a biomarker patent within Europe earlier this year.
“Colorectal cancer is one of the major killers globally … it’s also remarkable that colorectal cancer is one of the most curable cancers if detected early,” Lockett says.
He continues, “ColoSTAT is a blood test for bowel cancer. It’s based on the detection of proteins that change in concentration in the blood, in the situation of cancer versus normal disease. It’s designed to be a cost-effective, highly clinically effective and accessible test that will be taken by many people.”